Executive Team

Executive Team is currently a Scientific Advisor at C2i Genomics. Prior to this, Executive Team was a Postdoctoral Research Fellow at New York Genome Center from November 2016 to October 2019. There, they developed liquid biopsy approaches for early-detection of solid cancers (cancer screening) and for the optimization of cancer treatment by utilizing real-time tumor DNA monitoring in patient’s plasma (ctDNA). Executive Team co-led the project from conception to proof-of-principle and initiated the path towards commercialization.

Achievements during their time at New York Genome Center include leading a cross organization effort involving lab staff, computational biologists and sequencing method development scientists; developing novel IP and designing proof-of-principle experiments; developing and maintaining clinical collaborations with wide clinical consortium for clinical validation; being a finalist in Cornell Bioventure business plan competition (10 week course) - market and value proposition analysis, engaging stakeholders - clinicians, payers, regulators; leading the commercialization of the technology to a newCo and developing the company portfolio - Competitive assessment, Market analysis and pricing, Regulatory and Business strategy. Engaging potential investors, incubators and strategic partners. Executive Team's research was supported by the prestigious EMBO long-term fellowship and have been recognized by additional prestigious awards (see awards below).